January 4, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for maribavir (SHP620), […]
US-based ANI Pharmaceuticals has purchased the rights from AstraZeneca to market Atacand, Atacand HCT, Arimidex and Casodex tablets in the country. The deal, which included new drug applications (NDAs) and a licence to the trademarks […]
Mallinckrodt has signed an agreement to purchase all outstanding shares of Sucampo Pharmaceuticals for around $1.2bn. Under the agreement, Mallinckrodt will acquire Sucampo’s commercial and development assets, including the US Food and Drug Administration (FDA) […]
The PD-1/PD-L1 ICI class is becoming a new standard of care for patients with advanced NSCLC, demonstrating efficacy versus chemotherapy in first- and second-line treatment. There continue to be no safety concerns, as safety data […]
An investigational drug under development to mitigate symptoms associated with opioid withdrawal and facilitate completion of opioid discontinuation treatment. US WorldMeds has the rights to commercialize lofexidine in the U.S., which is currently approved as […]